UBS downgrades Avadel Pharmaceuticals stock to Neutral following Alkermes acquisition deal
NegativeFinancial Markets

UBS has downgraded Avadel Pharmaceuticals' stock to a neutral rating following the recent acquisition deal with Alkermes. This decision reflects concerns about the potential impact of the acquisition on Avadel's future performance. Investors should pay attention to how this change in rating might affect market perceptions and the stock's trajectory moving forward.
— Curated by the World Pulse Now AI Editorial System








